Published in Dig Dis Sci on January 26, 2010
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology (2010) 2.47
Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int (2014) 2.21
Energy metabolism in the liver. Compr Physiol (2014) 1.88
Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology (2015) 1.81
Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania. Thyroid (2012) 1.62
Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis. J Hepatol (2014) 1.48
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol (2014) 1.25
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol (2010) 1.18
Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci (2011) 1.16
Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One (2012) 1.13
The role of metformin in the management of NAFLD. Exp Diabetes Res (2011) 1.09
Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS One (2011) 1.08
Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol (2011) 1.05
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors (2010) 1.04
SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit (2011) 1.03
PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI family heart study. Int J Obes (Lond) (2012) 1.03
PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res (2012) 1.03
Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol (2010) 1.01
FOXO1 increases CCL20 to promote NF-κB-dependent lymphocyte chemotaxis. Mol Endocrinol (2012) 0.96
Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol (2014) 0.95
GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One (2012) 0.95
Physical activity and nutrition attitudes in obese Hispanic children with non-alcoholic steatohepatitis. World J Gastroenterol (2011) 0.91
Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci (2014) 0.91
A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun (2015) 0.90
Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut Liver (2013) 0.89
Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. J Obes (2010) 0.89
The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol (2010) 0.89
Molecular Interactions between NAFLD and Xenobiotic Metabolism. Front Genet (2013) 0.88
Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression. Eur Radiol (2011) 0.88
Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One (2014) 0.87
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation. J Biol Chem (2011) 0.87
CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol (2013) 0.87
Sex and race differences in the prevalence of fatty liver disease as measured by computed tomography liver attenuation in European American and African American participants of the NHLBI family heart study. Eur J Gastroenterol Hepatol (2012) 0.87
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One (2013) 0.86
Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med (2014) 0.84
Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterol Hepatol Bed Bench (2016) 0.84
Qushi Huayu Decoction Inhibits Hepatic Lipid Accumulation by Activating AMP-Activated Protein Kinase In Vivo and In Vitro. Evid Based Complement Alternat Med (2013) 0.84
p27 Is a critical prognostic biomarker in non-alcoholic steatohepatitis-related hepatocellular carcinoma. Int J Mol Sci (2013) 0.84
Intracellular lipid content is a key intrinsic determinant for hepatocyte viability and metabolic and inflammatory states in mice. Am J Physiol Endocrinol Metab (2013) 0.83
Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. Hepat Med (2010) 0.83
Dietary oleate has beneficial effects on every step of non-alcoholic Fatty liver disease progression in a methionine- and choline-deficient diet-fed animal model. Diabetes Metab J (2011) 0.83
High-frequency ultrasound imaging for longitudinal evaluation of non-alcoholic fatty liver disease progression in mice. Ultrasound Med Biol (2011) 0.83
The crude extract from puerariae flower exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice. Evid Based Complement Alternat Med (2012) 0.82
Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight. Nutrients (2014) 0.82
Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets. Dig Dis Sci (2012) 0.82
Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis (2013) 0.82
The effect of berberis vulgaris extract on transaminase activities in non-alcoholic Fatty liver disease. Hepat Mon (2015) 0.81
Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress. J Biomed Sci (2012) 0.81
Nonalcoholic Fatty Liver Disease Relationship with Metabolic Syndrome in Class III Obesity Individuals. Biomed Res Int (2015) 0.81
The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study. Atherosclerosis (2013) 0.80
Hepatic SH2B1 and SH2B2 regulate liver lipid metabolism and VLDL secretion in mice. PLoS One (2013) 0.79
The effect of taurine on hepatic steatosis induced by thioacetamide in zebrafish (Danio rerio). Dig Dis Sci (2011) 0.79
Carnosic acid (CA) prevents lipid accumulation in hepatocytes through the EGFR/MAPK pathway. J Gastroenterol (2012) 0.79
Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment. World J Gastroenterol (2013) 0.79
Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease. Sci Rep (2015) 0.79
KSRP is critical in governing hepatic lipid metabolism through controlling Per2 expression. J Lipid Res (2014) 0.79
Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Sci Rep (2015) 0.79
Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. Environ Health Prev Med (2012) 0.79
Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease. Int J Clin Exp Pathol (2011) 0.78
Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease. Korean J Intern Med (2013) 0.78
Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism. PLoS One (2012) 0.78
Analysis of vanin-1 upregulation and lipid accumulation in hepatocytes in response to a high-fat diet and free fatty acids. J Clin Biochem Nutr (2012) 0.78
Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. Clin Mol Hepatol (2012) 0.78
Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference. J Magn Reson Imaging (2015) 0.78
Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis. World J Gastroenterol (2014) 0.78
S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Des Devel Ther (2013) 0.77
Tuberculosis and hepatic steatosis are prevalent liver pathology findings among HIV-infected patients in South Africa. PLoS One (2015) 0.77
Markers of liver function and inflammatory cytokines modulation by aerobic versus resisted exercise training for nonalcoholic steatohepatitis patients. Afr Health Sci (2014) 0.77
miR-149 controls non-alcoholic fatty liver by targeting FGF-21. J Cell Mol Med (2016) 0.77
Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.77
CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. World J Hepatol (2013) 0.77
Auricularia polytricha aqueous extract supplementation decreases hepatic lipid accumulation and improves antioxidative status in animal model of nonalcoholic fatty liver. Biomedicine (Taipei) (2014) 0.77
Dietary walnut oil modulates liver steatosis in the obese Zucker rat. Eur J Nutr (2013) 0.77
Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial. Nutr J (2013) 0.76
Body iron, serum ferritin, and nonalcoholic fatty liver disease. Korean J Hepatol (2012) 0.76
Glycosyltransferases and non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.76
The impact of weight changes on nonalcoholic Fatty liver disease in adult men with normal weight. Korean J Fam Med (2014) 0.76
Glutamate dehydrogenase activator BCH stimulating reductive amination prevents high fat/high fructose diet-induced steatohepatitis and hyperglycemia in C57BL/6J mice. Sci Rep (2016) 0.75
Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev (2011) 0.75
Association between circulating inflammatory molecules and alcoholic liver disease in men. Cell Stress Chaperones (2016) 0.75
Metformin: a therapeutic option for treating nonalcoholic fatty liver disease. Dig Dis Sci (2010) 0.75
Short- and Long-Term Reproducibility of Intrahepatic Lipid Quantification by 1H-MR Spectroscopy and CT in Obesity. J Comput Assist Tomogr (2016) 0.75
Diverse roles of the nucleic acid-binding protein KHSRP in cell differentiation and disease. Wiley Interdiscip Rev RNA (2015) 0.75
Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes. Iran Biomed J (2014) 0.75
Constitutive Activation of the Nlrc4 Inflammasome Prevents Hepatic Fibrosis and Promotes Hepatic Regeneration after Partial Hepatectomy. Mediators Inflamm (2015) 0.75
Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia. J Clin Biochem Nutr (2012) 0.75
Thymic NF-κB-inducing kinase regulates CD4(+) T cell-elicited liver injury and fibrosis in mice. J Hepatol (2017) 0.75
Increased bone mineral density in patients with non-alcoholic steatohepatitis. World J Hepatol (2013) 0.75
Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription of srebp1. Oncotarget (2016) 0.75
Iron Status and Metabolic Syndrome in Patients with Non-Alcoholic Fatty Liver Disease. Middle East J Dig Dis (2016) 0.75
Liver tumors in children with metabolic disorders. Transl Pediatr (2015) 0.75
Development and Application of Low-Carbohydrates and Low-Simple Sugar Nutrition Education Materials for Non-Alcoholic Fatty Liver Disease Patients. Clin Nutr Res (2015) 0.75
Antioxidant vitamins in the context of nonalcoholic fatty liver disease in obese children and adolescents. Rev Paul Pediatr (2013) 0.75
Omega-3 fatty acids: a promising alternative treatment approach for patients with nonalcoholic fatty liver disease. Dig Dis Sci (2010) 0.75
Pathophysiology after pancreaticoduodenectomy. World J Gastroenterol (2015) 0.75
Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm: Propensity score matching analysis. PLoS One (2017) 0.75
Serum and Liver Tissue Metabonomic Study on Fatty Liver in Rats Induced by High-Fat Diet and Intervention Effects of Traditional Chinese Medicine Qushi Huayu Decoction. Evid Based Complement Alternat Med (2017) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 14.15
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 9.59
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Tumor necrosis factor (TNF). Science (1985) 8.80
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med (2000) 7.97
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology (2002) 6.62
Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev (2002) 6.46
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal (2001) 5.86
Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med (2005) 5.38
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 5.32
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology (2001) 5.07
AGA technical review on nonalcoholic fatty liver disease. Gastroenterology (2002) 4.61
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 4.05
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut (2008) 3.88
Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation (2002) 3.84
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA (1999) 3.56
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 3.51
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (2002) 3.29
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 3.16
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology (2008) 3.15
Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology (2006) 3.02
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol (2006) 2.96
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology (2008) 2.91
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol (2005) 2.84
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology (2008) 2.83
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis (2006) 2.83
Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging (1995) 2.77
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med (2007) 2.76
Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (2001) 2.69
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol (2007) 2.54
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (2007) 2.48
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol (1997) 2.38
Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol (2007) 2.37
Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.35
Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology (2002) 2.34
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med (2004) 2.29
Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med (1998) 2.26
Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol (2009) 2.26
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology (2008) 2.23
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut (2004) 2.15
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci (1998) 2.12
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol (2006) 2.07
Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology (2004) 2.06
The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction. Int J Obes Relat Metab Disord (2001) 2.05
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2000) 1.96
Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med (1998) 1.93
Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology (2001) 1.92
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci (2000) 1.85
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 1.85
Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr (2005) 1.84
The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg (2004) 1.83
Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol (2005) 1.80
Is NASH underdiagnosed among African Americans? Am J Gastroenterol (2002) 1.79
Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol (2004) 1.78
Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 1.75
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther (2006) 1.74
Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther (2001) 1.73
Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol (2007) 1.72
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2006) 1.67
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int (2013) 1.13
Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol (2008) 0.96
Improving the quality of colonoscopy bowel preparation using an educational video. Can J Gastroenterol (2013) 0.90
A case of biliopleural fistula in a patient with hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 0.84
Chronic methadone use, poor bowel visualization and failed colonoscopy: a preliminary study. World J Gastroenterol (2012) 0.81
Prevalence of Helicobacter pylori infection in bariatric patients: a histologic assessment. Surg Obes Relat Dis (2012) 0.80
A patient with abdominal pain and markedly elevated transaminase levels after cholecystectomy. Nat Clin Pract Gastroenterol Hepatol (2006) 0.79
Entecavir therapy in a hepatitis B-related decompensated cirrhotic patient. South Med J (2008) 0.79
Progressive multifocal leukoencephalopathy with peripheral demyelinating neuropathy in a liver transplant patient. Gastroenterol Hepatol (N Y) (2007) 0.77
The need for liver biopsy in a patient with acute HCV infection. Nat Clin Pract Gastroenterol Hepatol (2008) 0.76
Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant (2012) 0.76
Aggressive systemic mastocytosis presenting with hepatic cholestasis. Eur J Gastroenterol Hepatol (2007) 0.76
Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. Eur J Gastroenterol Hepatol (2017) 0.75
Outpatient management of cirrhosis. South Med J (2006) 0.75
Extrahepatic manifestations of hepatitis C. South Med J (2005) 0.75